$mozart, the triple negative patients (as stated in my previous post) do not have any of the target receptors that drugs aim to influence.
The puzzle to intervene and influence parthways as to allow the body’s immune system to correct requires further research. Yet, the ptx-200 compound seems to touch on this even though a higher potency is now known to intercept receptor oestrogen pathway ER+ sufferers.
The Phase 2 study will shed more light on this.
As for the primary care factor ( chemo current status), this might also change if the results of the phase 2 study are replicated and underscore chemo alone.
Hope this helps.
PTX Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
